赖氨酰氧化酶抑制剂研究进展
The Research Progress of Lysyl Oxidase Inhibitors
DOI: 10.12677/hjmce.2025.133029, PDF,   
作者: 彭 斌*, 张 影, 张子龙：内蒙古医科大学药学院，内蒙古 呼和浩特；张 捷#：中国人民解放军总医院第九医学中心，北京；王冬梅#：中国医学科学院&北京协和医学院药物研究所，北京
关键词: 赖氨酰氧化酶；赖氨酰氧化酶样蛋白；癌症；纤维化；抑制剂；Lysyl Oxidase； Lysyl Oxidase-Like Protein； Cancer； Fibrosis； Inhibitor
摘要: 赖氨酰氧化酶家族是一类铜依赖的胺氧化酶，包括赖氨酰氧化酶(LOX)和赖氨酰氧化酶样蛋白1、2、3、4 (LOXL1, 2, 3, 4)。赖氨酰氧化酶催化弹性蛋白和胶原的交联反应，促进细胞迁移和转移。LOX与许多疾病相关，包括炎症性疾病、纤维化疾病和癌症。本文综述了赖氨酰氧化酶的结构、功能及其抑制剂的研究进展。
Abstract: The lysyl oxidase family is a group of copper-dependent amine oxidases that include lysyl oxidase (LOX) and lysyl oxidase-like-1, 2, 3 and 4 (LOXL1, 2, 3, 4). Lysyl oxidase catalyzes cross-linking reactions of elastin and collagen, promoting cell migration and metastasis. LOX is associated with many diseases, including inflammatory diseases, fibrotic diseases, and cancer. This article reviews the progress of research on the structure and function of lysyl oxidase and its inhibitors.
文章引用：彭斌, 张影, 张子龙, 张捷, 王冬梅. 赖氨酰氧化酶抑制剂研究进展[J]. 药物化学, 2025, 13(3): 277-292. https://doi.org/10.12677/hjmce.2025.133029

参考文献

[1] Li, T., Wu, C., Gao, L., Qin, F., Wei, Q. and Yuan, J. (2018) Lysyl Oxidase Family Members in Urological Tumorigenesis and Fibrosis. Oncotarget, 9, 20156-20164. [Google Scholar] [CrossRef] [PubMed]
[2] Ferreira, S., Saraiva, N., Rijo, P. and Fernandes, A.S. (2021) LOXL2 Inhibitors and Breast Cancer Progression. Antioxidants, 10, Article 312. [Google Scholar] [CrossRef] [PubMed]
[3] Grau-Bové, X., Ruiz-Trillo, I. and Rodriguez-Pascual, F. (2015) Origin and Evolution of Lysyl Oxidases. Scientific Reports, 5, Article No. 10568. [Google Scholar] [CrossRef] [PubMed]
[4] Rosell-García, T., Rivas-Muñoz, S., Colige, A. and Rodriguez-Pascual, F. (2022) Cleavage of LOXL1 by BMP1 and ADAMTS14 Proteases Suggests a Role for Proteolytic Processing in the Regulation of LOXL1 Function. International Journal of Molecular Sciences, 23, Article 3285. [Google Scholar] [CrossRef] [PubMed]
[5] Attaran, S., Skoko, J.J., Hopkins, B.L., Wright, M.K., Wood, L.E., Asan, A., et al. (2021) Peroxiredoxin-1 Tyr194 Phosphorylation Regulates LOX-Dependent Extracellular Matrix Remodelling in Breast Cancer. British Journal of Cancer, 125, 1146-1157. [Google Scholar] [CrossRef] [PubMed]
[6] Peng, T., Deng, X., Tian, F., Li, Z., Jiang, P., Zhao, X., et al. (2019) The Interaction of LOXL2 with GATA6 Induces VEGFA Expression and Angiogenesis in Cholangiocarcinoma. International Journal of Oncology, 55, 657-670. [Google Scholar] [CrossRef] [PubMed]
[7] Martínez-González, J., Varona, S., Cañes, L., Galán, M., Briones, A., Cachofeiro, V., et al. (2019) Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges. Biomolecules, 9, Article 610. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, X., Wang, Q., Wu, J., Wang, J., Shi, Y. and Liu, M. (2018) Crystal Structure of Human Lysyl Oxidase-Like 2 (hLOXL2) in a Precursor State. Proceedings of the National Academy of Sciencesof the United States of America, 115, 3828-3833. [Google Scholar] [CrossRef] [PubMed]
[9] Vallet, S.D., Guéroult, M., Belloy, N., Dauchez, M. and Ricard-Blum, S. (2019) A Three-Dimensional Model of Human Lysyl Oxidase, a Cross-Linking Enzyme. ACS Omega, 4, 8495-8505. [Google Scholar] [CrossRef] [PubMed]
[10] Löser, R., Kuchar, M., Wodtke, R., Neuber, C., Belter, B., Kopka, K., et al. (2023) Lysyl Oxidases as Targets for Cancer Therapy and Diagnostic Imaging. ChemMedChem, 18, e202300331. [Google Scholar] [CrossRef] [PubMed]
[11] Rowbottom, M.W., Bain, G., Calderon, I., Lasof, T., Lonergan, D., Lai, A., et al. (2017) Identification of 4-(Aminomethyl)-6-(Trifluoromethyl)-2-(Phenoxy)Pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2). Journal of Medicinal Chemistry, 60, 4403-4423. [Google Scholar] [CrossRef] [PubMed]
[12] Setargew, Y.F.I., Wyllie, K., Grant, R.D., Chitty, J.L. and Cox, T.R. (2021) Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours. Cancers, 13, Article 491. [Google Scholar] [CrossRef] [PubMed]
[13] Hu, L., Wang, J., Wang, Y., Wu, L., Wu, C., Mao, B., et al. (2020) LOXL1 Modulates the Malignant Progression of Colorectal Cancer by Inhibiting the Transcriptional Activity of YAP. Cell Communication and Signaling, 18, Article No. 148. [Google Scholar] [CrossRef] [PubMed]
[14] Yuan, R., Li, Y., Yang, B., Jin, Z., Xu, J., Shao, Z., et al. (2021) LOXL1 Exerts Oncogenesis and Stimulates Angiogenesis through the Loxl1-Fbln5/αvβ3 Integrin/Fak-MAPK Axis in ICC. Molecular Therapy-Nucleic Acids, 23, 797-810. [Google Scholar] [CrossRef] [PubMed]
[15] Liburkin-Dan, T., Toledano, S. and Neufeld, G. (2022) Lysyl Oxidase Family Enzymes and Their Role in Tumor Progression. International Journal of Molecular Sciences, 23, Article 6249. [Google Scholar] [CrossRef] [PubMed]
[16] Kasashima, H., Yashiro, M., Okuno, T., Miki, Y., Kitayama, K., Masuda, G., et al. (2018) Significance of the Lysyl Oxidase Members Lysyl Oxidase Like 1, 3, and 4 in Gastric Cancer. Digestion, 98, 238-248. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, C., Guo, T., Sakai, A., Ren, S., Fukusumi, T., Ando, M., et al. (2019) A Novel Splice Variant of LOXL2 Promotes Progression of Human Papillomavirus-Negative Head and Neck Squamous Cell Carcinoma. Cancer, 126, 737-748. [Google Scholar] [CrossRef] [PubMed]
[18] Peinado, H., del Carmen Iglesias-de la Cruz, M., Olmeda, D., Csiszar, K., Fong, K.S.K., Vega, S., et al. (2005) A Molecular Role for Lysyl Oxidase-Like 2 Enzyme in Snail Regulation and Tumor Progression. The EMBO Journal, 24, 3446-3458. [Google Scholar] [CrossRef] [PubMed]
[19] Li, R., Zhao, W., Fang, F., Zhuang, C., Zhang, X., Yang, X., et al. (2015) Lysyl Oxidase-Like 4 (LOXL4) Promotes Proliferation and Metastasis of Gastric Cancer via FAK/Src Pathway. Journal of Cancer Research and Clinical Oncology, 141, 269-281. [Google Scholar] [CrossRef] [PubMed]
[20] Li, R., Wang, Y., Zhang, X., Feng, M., Ma, J., Li, J., et al. (2019) Exosome-Mediated Secretion of LOXL4 Promotes Hepatocellular Carcinoma Cell Invasion and Metastasis. Molecular Cancer, 18, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[21] Shao, J., Lu, J., Zhu, W., Yu, H., Jing, X., Wang, Y., et al. (2019) Derepression of LOXL4 Inhibits Liver Cancer Growth by Reactivating Compromised P53. Cell Death & Differentiation, 26, 2237-2252. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, Y., Jiang, W., Yang, J., Huang, J., Kang, G., Hu, H., et al. (2019) Downregulation of Lysyl Oxidase‐Like 4 LOXL4 by miR-135a-5p Promotes Lung Cancer Progression in Vitro and in Vivo. Journal of Cellular Physiology, 234, 18679-18687. [Google Scholar] [CrossRef] [PubMed]
[23] Chen, L., Li, S. and Li, W. (2018) LOX/LOXL in Pulmonary Fibrosis: Potential Therapeutic Targets. Journal of Drug Targeting, 27, 790-796. [Google Scholar] [CrossRef] [PubMed]
[24] Bahmani, M., Ziamajidi, N., Hashemnia, M. and Abbasalipourkabir, R. (2020) Human Umbilical Cord-Derived Mesenchymal Stem Cells Conditioned Medium Ameliorates CCL4-Induced Liver Fibrosis through Regulation of Expression and Activity of Liver Lysyl Oxidase. Toxin Reviews, 40, 971-984. [Google Scholar] [CrossRef] 
[25] Zhang, X., Li, X., Zhou, W., Liu, X., Huang, J., Zhang, Y., et al. (2020) Serum Lysyl Oxidase Is a Potential Diagnostic Biomarker for Kidney Fibrosis. American Journal of Nephrology, 51, 907-918. [Google Scholar] [CrossRef] [PubMed]
[26] Saifi, M.A. and Godugu, C. (2020) Inhibition of Lysyl Oxidase Ameliorates Renal Injury by Inhibiting CD44-Mediated Pericyte Detachment and Loss of Peritubular Capillaries. Life Sciences, 243, Article 117294. [Google Scholar] [CrossRef] [PubMed]
[27] El Hajj, E.C., El Hajj, M.C., Ninh, V.K., et al. (2017) Cardioprotective Effects of Lysyl Oxidase Inhibition Against Adverse Extracellular Matrix Remodeling and Cardiomyocyte Apoptosis. The FASEB Journal, 31, 881.5. [Google Scholar] [CrossRef] 
[28] Zhao, R., Wang, J., Qin, L., Zhang, X. and Mei, Y. (2020) Stevioside Improved Hyperglycemia-Induced Cardiac Dysfunction by Attenuating the Development of Fibrosis and Promoting the Degradation of Established Fibrosis. Journal of Functional Foods, 68, Article 103895. [Google Scholar] [CrossRef] 
[29] Huang, M., Cai, G., Baugh, L.M., Liu, Z., Smith, A., Watson, M., et al. (2020) Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis through Lysyl Oxidase-Like 4: New Evidence from Three-Dimensional Skin-Like Tissues. Arthritis & Rheumatology, 72, 791-801. [Google Scholar] [CrossRef] [PubMed]
[30] Chanoki, M., Ishii, M., Kobayashi, H., Fushida, H., Yashiro, N., Hamada, T., et al. (2006) Increased Expression of Lysyl Oxidase in Skin with Scleroderma. British Journal of Dermatology, 133, 710-715. [Google Scholar] [CrossRef] [PubMed]
[31] Hajdú, I., Kardos, J., Major, B., Fabó, G., Lőrincz, Z., Cseh, S., et al. (2018) Inhibition of the LOX Enzyme Family Members with Old and New Ligands. Selectivity Analysis Revisited. Bioorganic & Medicinal Chemistry Letters, 28, 3113-3118. [Google Scholar] [CrossRef] [PubMed]
[32] Tang, S.S., Trackman, P.C. and Kagan, H.M. (1983) Reaction of Aortic Lysyl Oxidase with Beta-Aminopropionitrile. Journal of Biological Chemistry, 258, 4331-4338. [Google Scholar] [CrossRef] [PubMed]
[33] Yang, X., Li, S., Li, W., Chen, J., Xiao, X., Wang, Y., et al. (2012) Inactivation of Lysyl Oxidase by β-Aminopropionitrile Inhibits Hypoxia-Induced Invasion and Migration of Cervical Cancer Cells. Oncology Reports, 29, 541-548. [Google Scholar] [CrossRef] [PubMed]
[34] Zhao, L., Niu, H., Liu, Y., Wang, L., Zhang, N., Zhang, G., et al. (2019) LOX Inhibition Downregulates MMP-2 and MMP-9 in Gastric Cancer Tissues and Cells. Journal of Cancer, 10, 6481-6490. [Google Scholar] [CrossRef] [PubMed]
[35] Keiser, H.R. and Sjoerdsma, A. (1967) Studies on Beta-Aminopropionitrile in Patients with Scleroderma. Clinical Pharmacology & Therapeutics, 8, 593-602. [Google Scholar] [CrossRef] [PubMed]
[36] Hecht, J.R., Benson, A.B., Vyushkov, D., Yang, Y., Bendell, J. and Verma, U. (2017) A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic Kras Mutant Colorectal Adenocarcinoma. The Oncologist, 22, 243-E23. [Google Scholar] [CrossRef] [PubMed]
[37] Hutchinson, J.H., Rowbottom, M.W., Lonergan, D., Darlington, J., Prodanovich, P., King, C.D., et al. (2017) Small Molecule Lysyl Oxidase-Like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX. ACS Medicinal Chemistry Letters, 8, 423-427. [Google Scholar] [CrossRef] [PubMed]
[38] Rowbottom, M.W., Hutchinson, J.H. and Lonergan, D. (2016) Lysyl Oxidase-Like 2 Inhibitors and Uses Thereof. WO Patent No. 2016144702.
[39] Rowbottom, M.W., Hutchinson, J.H. and Calderon, I. (2016) Fluorinated Lysyl Oxidase-Like 2 Nhibitors and Uses Thereof. WO Patent No. 2016144703.
[40] Rowbottom, M.W. and Hutchinson, J.H. (2017) Lysyl Oxidase-Like 2 Inhibitors and Uses Thereof. WO Patent No. 2017003862.
[41] Chang, J., Lucas, M.C., Leonte, L.E., Garcia-Montolio, M., Singh, L.B., Findlay, A.D., et al. (2017) Pre-Clinical Evaluation of Small Molecule LOXL2 Inhibitors in Breast Cancer. Oncotarget, 8, 26066-26078. [Google Scholar] [CrossRef] [PubMed]
[42] Schilter, H., Findlay, A.D., Perryman, L., Yow, T.T., Moses, J., Zahoor, A., et al. (2018) The Lysyl Oxidase Like 2/3 Enzymatic Inhibitor, PXS‐5153A, Reduces Crosslinks and Ameliorates Fibrosis. Journal of Cellular and Molecular Medicine, 23, 1759-1770. [Google Scholar] [CrossRef] [PubMed]
[43] Findlay, A.D., Foot, J.S., Buson, A., Deodhar, M., Jarnicki, A.G., Hansbro, P.M., et al. (2019) Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-Like 2/3. Journal of Medicinal Chemistry, 62, 9874-9889. [Google Scholar] [CrossRef] [PubMed]
[44] Findlay, A., Turner, C., Schilter, H., Deodhar, M., Zhou, W., Perryman, L., et al. (2021) An Activity-Based Bioprobe Differentiates a Novel Small Molecule Inhibitor from a LOXL2 Antibody and Provides Renewed Promise for Anti‐Fibrotic Therapeutic Strategies. Clinical and Translational Medicine, 11, e572. [Google Scholar] [CrossRef] [PubMed]
[45] Findlay, A., Turner, C., Deodhar, M., et al. (2018) Haloallylamine Pyrazole Derivative Inhibitors of Lysyl Oxidases and Uses Thereof. WO Patent No. 2018157190.
[46] Kim, E.K., Lim, C.H., Lee, K.Y., et al. (2023) Bicyclic Fused Ring Derivative or Salt Thereof and Pharmaceutical Composition Comprising Same. WO Patent No. 2023055124.
[47] Chitty, J.L., Yam, M., Perryman, L., Parker, A.L., Skhinas, J.N., Setargew, Y.F.I., et al. (2023) A First-in-Class Pan-Lysyl Oxidase Inhibitor Impairs Stromal Remodeling and Enhances Gemcitabine Response and Survival in Pancreatic Cancer. Nature Cancer, 4, 1326-1344. [Google Scholar] [CrossRef] [PubMed]
[48] Chaudhari, N., Findlay, A.D., Stevenson, A.W., Clemons, T.D., Yao, Y., Joshi, A., et al. (2022) Topical Application of an Irreversible Small Molecule Inhibitor of Lysyl Oxidases Ameliorates Skin Scarring and Fibrosis. Nature Communications, 13, Article No. 5555. [Google Scholar] [CrossRef] [PubMed]
[49] Findlay, A.D., Jarolimek, W., Deodhar, M., et al. (2024) Novel Selective Inhibitors of Lysyl Oxidases. WO Patent No. 2024044813.
[50] Leung, L., Niculescu-Duvaz, D., Smithen, D., Lopes, F., Callens, C., McLeary, R., et al. (2019) Anti-Metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships. Journal of Medicinal Chemistry, 62, 5863-5884. [Google Scholar] [CrossRef] [PubMed]
[51] Smithen, D.A., Leung, L.M.H., Challinor, M., Lawrence, R., Tang, H., Niculescu-Duvaz, D., et al. (2019) 2-Aminomethylene-5-Sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth. Journal of Medicinal Chemistry, 63, 2308-2324. [Google Scholar] [CrossRef] [PubMed]
[52] Leung, L., Niculescu, D.D., Springer, C., et al. (2024) Sulfoximines as Inhibitors of Lysyl Oxidase. WO Patent No. 2024003557.
[53] Rowbottom, M.W., Hutchinson, J.H. and Lonergan, D. (2018) Lysyl Oxidase-Like 2 Inhibitors and Uses Thereof. WO Patent No. 2018048930.
[54] Rowbottom, M.W. and Hutchinson, J.H. (2017) Quinolinone Lysyl Oxidase-Like 2 Inhibitors and Uses Thereof. WO Patent No. 2017139274.
[55] Rowbottom, M.W. and Hutchinson, J.H. (2017) Lysyl Oxidase-Like 2 Inhibitors and Uses Thereof. WO Patent No. 2017015221.
[56] Aljarah, M., Niculescu, D.D., Leung, L., et al. (2020) LOX Inhibitors. WO Patent No. 2020099886.
[57] Leung, L., North, K., Smithen, D., et al. (2019) Hexahydropyrrolo[3,4-c]Pyrrole Derivatives Useful as Lox Inhibitors. WO Patent No. 2019234418.
[58] Marais, R., Springer, C., Niculescu, D.D., et al. (2019) Lysyl Oxidase Inhibitors. WO Patent No. 2019073251.
[59] Clare, M., Kleppe, M., Li, X., et al. (2021) LOX Enzyme Inhibiting Methods and Compositions. WO Patent No. 2021216592.
[60] Clare, M., Du, J., Li, X., et al. (2023) LOX Enzyme Inhibiting Methods and Compositions. WO Patent No. 2023076567.
[61] Sahin, O., Mcinnes, C., Saatci, O., et al. (2022) Bithiazol Deratives as Inhibitors of Lysyl Oxidases. WO Patent No. 2022240476.
[62] Burchardt, E.R. (2006) Novel Lysyl Oxidase Inhibitors. DE Patent No. 102004056226.
[63] Gotteland, J., Gaillard, P. and Chvatchko, Y. (2003) Benzazole Derivatives for the Treatment of Scleroderma. WO Patent No. 2003047570.
[64] Wei, Y., Kim, T.J., Peng, D.H., Duan, D., Gibbons, D.L., Yamauchi, M., et al. (2017) Fibroblast-Specific Inhibition of TGF-β1 Signaling Attenuates Lung and Tumor Fibrosis. Journal of Clinical Investigation, 127, 3675-3688. [Google Scholar] [CrossRef] [PubMed]
[65] Chapman, H.A., Wei, Y., Montas, G., Leong, D., Golden, J.A., Trinh, B.N., et al. (2020) Reversal of TGFβ1-Driven Profibrotic State in Patients with Pulmonary Fibrosis. New England Journal of Medicine, 382, 1068-1070. [Google Scholar] [CrossRef] [PubMed]
[66] Brücher, B.L.D.M. and Jamall, I.S. (2023) Epistemology of the Origin of Cancer II: Fibroblasts Are the First Cells to Undergo Neoplastic Transformation. Cellular Physiology and Biochemistry, 57, 512-537. [Google Scholar] [CrossRef] [PubMed]
[67] Ahmed, R.S.I., Liu, G., Renzetti, A., Farshi, P., Yang, H., Soave, C., et al. (2016) Biological and Mechanistic Characterization of Novel Prodrugs of Green Tea Polyphenol Epigallocatechin Gallate Analogs in Human Leiomyoma Cell Lines. Journal of Cellular Biochemistry, 117, 2357-2369. [Google Scholar] [CrossRef] [PubMed]